

FAKULTNÍ
NEMOCNICE
U SV. ANNY
V BRNĚ



MUNI
MED

Oncology in ENT I

KOCHHK FNUSA

Clinic of Otorhinolaryngology and Head and Neck Surgery, Masaryk
university, Faculty St. Ann Hospital

Head: Ass. Prof. Gál Břetislav, MD, Ph.D.

Pekařská 53

656 91 Brno, Czech Republic





Incidence

Malignant tumors of head and neck represent in **men approx. 6 %**, in **women approx. 2 %** of all malignant tumors.


In CR incidence of ca orofarynx and oral cavity **12,7/100 000** in man and **4,6 /100 000** in woman (2012); increasing trend.

Incidence of larynx carcinoma was in CR **9,3/100 000** inhabitants in **men** and **1,1/100 000** inhabitants in **women** (2012).

Incidence partially depends on geographical site (increase from North to South)



Development of head and neck cancer incidence in CR





Therapeutic results of Head and Neck Cancer in relation to stage

Approximate 5-year survival

I. stage	91 %
II. stage	77 %
III. stage	61 %
IV. a	32 %
IV. b	25 %
IV. c	4 %

The prognosis of patients with the head and neck carcinomas is worsened due to frequent associated diseases. (hepatic cirrhosis, diseases of circulatory and breathing systems etc.).











Aim of clinical diagnosis

Determine

- **Verification** of malignancy; **determination of character** (grading) and **size of primary tumor**, staging. The result is **TNM** classification.
- **determination of performance status of organism**, incl. psychological and social status.



Clinical diagnosis, assessment of prognosis

- Complete history of disease
- Clinical examination - inspection, palpation incl. endoscopy
- Histology of primary tumor, lymphatic drainage (FNAB, FNAC), cytology diagnosis (HPV)
- Diagnostic imaging – CT, MR of the neck, X-ray of chest, better CT, sonography of abdomen; contrast imaging of esophagus, ev. endoscopy in case of dysphagia; PET-CT, PET-MR
- Functional examination: swallowing, phonation, breathing,
- Stomatology examination; Nutritive screening
- Exclusion of duplex tumors: prostate in man, gynecology in woman
- Special examination, if necessary: psychologic examination, social status and support, prevention (smoking)



History of disease - „Listen to patient, he is saying diagnosis“

HNSCC tumors (exception of glottic cancer) – some months without specific symptoms (as civilization disease – chron. pharyngitis, rhinosinusitis, laryngitis), later:

- Feeling of foreign body in pharynx, burning, pain, especially one-sided in swallowing spreading into ears, foetor ex ore
- dysphagia, limited movability of tongue, worse pronunciation – mumbling due to tongue fixation
- anorexia, cachexia
- bleeding
- trismus
- Impaired nose breathing, epistaxis, external deformities in face
- hoarseness, cough, dyspnea
- tumor on external neck



Aspection

Remove removable tooth prosthesis, consider pathological changes on mucous membrane, asymmetry changes in oropharynx

- non healing damage on mucous membrane
- hard tumor covered of mucous membrane, later disintegration into ulcer.
- exophytic tumors – patient frequently notices itself
- white and red stain persisting on palate, tongue, buccal mucosal membrane – necessary biopsy and watching.
- neck tumor

Palpation (+bimanual palpation)

- form and size in cm, site (localization), topographic description
- consistency - soft, elastic, fluctuant, firm or hard
- mobility - vertically or horizontally, fixed or adherent
- evaluation of borders of tumor



Imaging methods

- CT, MR of the neck, X-ray of chest, better CT, sonography of abdomen
- PET-CT, PET-MR in advanced stages of pts. with assumption of curative treatment
- contrast imaging of esophagus, eventually endoscopy in case of dysphagia

CT/5/125
Axiální
KL 1mm
CONTRAST

MR/1001/13
Axiální
KL-T1W_MV_TRA_SPIR
NECK

4273-155/18-2
14.5.2018
13:30:3

R

R

120.0 kV
367.0 mA
185.0 mAs
Velikost pixelu: 0.1438 mm
Pozice: 338.5 mm
W: 350 L: 60


ET: 7
TR: 552.9
TE: 20.8
Velikost pixelu: 0.417 mm
Pozice: 92.5 mm
DFOV: 25.W: 1159 L: 667

P

DFOV: 24.00 x 24.00cm

Undesirable side affects – CT: Radiation, MR: Small amount of Gadolinium could be stored in brain

M-classification: M_0 no proof for distant. meta,
 M_1 - exist proof for distant metastasis
thyroid gland cancer – metastases in lung M_1 (PUL)





Endoscopic evaluation („optic biopsy“)

- **Horizontal** – NBI, SPIES (Storz Professional Image Enhancement System – changes of color spectrum of tissues)
- **Vertical** - *Optical coherence tomography (OKT)*, - radiation similar to infrared light penetrating 1-3 mm into depth; images issues in vertical section

Narrow Band Imaging




White light




NBI filter



NBI light



415 nm 540 nm



NBI image



Color adjustment





Classification of intraepithelial capillary vascular loops

The highest changes of vascular microarchitecture, the most significant probability of malignancy.



Narrow band imaging

Indication

- screening – early diagnosis
- Follow up after oncology treatment
- During evaluation or surgery for aimed biopsy


Limitations

- stagnation of saliva, mucous
- hyperkeratosis
- Influence of age, gender, lifestyle
- False positivity – laryngeal papillomatosis


Classification of intraepithelial capillary vascular loops in esophageal tumors. Inoue – progressive loss of vascular microarchitecture

		Type I	Normal	Negative for malignancy	
		Type II	Esophagitis	Indefinite for neoplasia	
		Type III	Esophagitis /LGIN	Noninvasive LGIN	
		Type IV (m1)	HGIN/CIS	Noninvasive HGIN	EMR/ ESD
		Type V ₁ (m1)			
		Type V ₂ (m2)	SCC	Noninvasive HGIN	
		Type V ₃ (m3/sm1)			ESD/ surgery
		Type V _N (sm2/deeper)		Invasive carcinoma	

Type I




Type III




Classification of SCC oral cavity. (Shibahara et al. 2013)

Type II




Type IV




18/05/2018
06:47:45

■■■/---(0/1)
Eh:A5 Cm:1



18/05/2018
06:46:38

■■■/---(0/1)
Eh:B7 Cm:1





Quality of life (QOL)

- Endeavor to safe and improve. QOL is possibly limiting factor for oncologic treatment.
- Measurement of QOL – Karnofski scale, ECOG performance status
- Measurement of QOL after oncologic treatment - psychometric questionnaires (Quality Of Life Questionnaire), for inst. QLQ-C30, QLQ-N&N37 a QLQ-H&N35

ECOG performance status

Grade	Description of patient
0	Fully active, able to carry on all predisease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work
2	Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours
3	Capable of only limited self-care; confined to bed or chair more than 50% of waking hours
4	Completely disabled; cannot carry on any self-care; totally confined to bed or chair
5	Dead

Source: Eastern Clinical Oncology Group



Karnofski scale

Score, %	State of Health
100	Healthy, no symptoms or signs of disease
90	Capable of normal activity, few symptoms or signs of disease
80	Normal activity with some difficulty, some symptoms or signs
70	Caring for self, not capable of normal activity or work
60	Requiring some help, can take care of most personal requirements
50	Requires help often, requires frequent medical care
40	Disabled, requires special care and help
30	Severely disabled, hospital admission indicated but no risk of death
20	Very ill, urgently requiring admission, requires supportive measures or treatment



Possibility of improvement of therapeutical results

- **preventive programs** aimed on risk groups (smoking, alcohol, etc.)
- **earlier detection** – increased oncologic „vigilance“ of family doctors and specialists
- **new methods of treatment** – new chemotherapeutics - new drugs, new protocols, immunotherapy, gene therapy, irradiation - new regimens, new methods in surgery
- suitable **individual adaptation of current therapeutical procedures** prognostic factors should be found – for instance evaluation of proliferation, apoptosis, DNA ploidy



Prognostic factors

- In relation to **patient** (Age, tobacco use, alcohol abuse, the whole status of organism, Immunology)
- In relation to **treatment** (tumors responding better to neoadjuvant treatment have better prognosis and they are suitable for treatment damaging genome (chemo, radiotherapy)
- In relation to **disease**



Prognostic factors in relation to disease

- primary localization
- **TNM stage** - TNM classification of malignant tumors, International Union Against Cancer (UICC)
- serum tumor markers (CEA, SCCA, TPA, CYFRA-21-1)
- **Histologic differentiation** („grading“ according to Broder)
- **Predictive biomarkers**




Biomarkers

Help to identify high-risk patients who may benefit from a more aggressive treatment approach.

Help to identify patients who are resistant to radiotherapy or chemotherapy, potentially avoiding the morbidity of ineffective therapies.

May serve as targets for biologic therapies.



Hanahan D, Weinberg RA: The Hallmarks of cancer. Cell 100:57-70, 2000. (8496 citations)




Targeted therapy, Precise therapy


- Higher expression of EGFR in 70-100 % HNSCC
- Blocking of signal pathway
- Activation of ADCC (**A**ntibody-**D**ependent **C**ellular **C**ytotoxicity)
- Activation on complement depended cytotoxicity
- Dependence of outcome on genetic alterations

Precise therapy include mainly genomic aspects in diagnosis and treatment.

Signal pathway of EGFR in carcinogenesis



Mechanism of effect inhibitors EGFR



- **More targeted antitumor therapy and lower undesirable effect than CHT**
- **EGFR receptors not present in hematopoietic tissue, but are present in skin, liver and GIT.**
- **Consequence of this are **undesirable effect:** diarrhea, rash, hypomagnesemia**



Rash, 14 days after end of therapy (RT+Cetuximab)





Addition of **p-16/HPV status** to evaluation of existing markers could be very helpful in prediction of treatment outcome in **oropharyngeal cancer**.

Prevalence of HPV positivity is given about **60%** in Czech population.

Checkpoint inhibitors – part of multimodal treatment

PD-1, PD-L1 (nivolumab, pembrolizumab) a CTLA-4 inhibitors: (ipilimumab)

Immune-oncology





Independent risk faktor for survival! Increasing Time to Treatment Initiation

Growth from a tumor of 1 g (the minimum size detectable) to a potentially lethal mass of 1 kg requires only 10 further doubling of cell number (DeVita: Cancer)

Colin T. Murphy, Thomas J. Galloway, Elizabeth A. Handorf, et al.:
Survival Impact of Increasing Time to Treatment Initiation
for Patients With Head and Neck Cancer in the United States. J Clin Oncol
34:169-178. © 2015

51,655 pts with HNSCC. Number of days from diagnosis to treatment initiation **61 to 90** days compared with less than 30 days independently increased risk of death (Cox regress analysis, HR, 1.13; 95% CI, 1.08 to 1.19)

Theory vs. reality

68 y patient, teacher

1/2018 pain in neck

2/2018 GP gave antibiotics


20/4 2018 evaluated on ENT

Taken sample - cT4 cN3 M0, p16 +

11/6 2018 supposed onset of CHRT

18/05/2018
13:25:10

■■■/---(0/1)
Eh:A5 Cm:1



CT9/34
Axiální
3.0 Neck CE
Krk
IOMERON



2.8.1950
67 Y M
1000571741
26-4-2018
07:47:37

120.0 kV
100.0 mA
50.0 mAs
Velikost pixelu: 0,1454 mm
Pozice: -863.5 mmr
W: 350 L: 40

DFOV: 23.24 x 23.24 cm



TNM classification

- Developed by Pierre Denoix v years 1942-1952; 2017 - **8. edition**
- Separately assessment of primary tumor (T), local metastasis (N) and distant metastasis (M)
- Basic philosophy – more advanced tumor, worse prognosis

Aims:

1. Helps clinician in treatment planning
2. Give information about prognosis
3. Helps in describing treatment outcomes
4. Make easier exchange of information between treatment centers
5. Helps in research HNSCC in man
6. Support activities in fight against malignant tumors



8th edition of TNM classification

- **Published in December 2016, Czech edition 4/2018.**
- **Main change in comparison with 7. ed. Is separate classification of p16+ oropharyngeal cancer**



HNSSC therapy

- **Curative** – induce permanent remission
- **Palliative** – to stop tumor growth
- **Symptomatic** (Best Supportive Care, BSC) – treat only symptoms (pain, food intake, bleeding, breathing)

Localized HNSCC– separate treatment only **surgery** or **radiotherapy** (not systemic treatment as a „definitive“ treatment)

Surgery

- **Curative** – complete removal of tumor tissue (R_0 resection)
- **Palliative** – to reduce tumor mass and improve usage of other treatment options.

Chemotherapy – only in combination with radiotherapy



Organ saving protocol

- **The aim – preservation of the organ and its function**
- **Surgery is avoided or minimized**
- **Organ preservation should not sacrifice length of survival**
- **Indication: patient with locally advanced but resectable tumor**



Criterion for Treatment choice

Overall survival, time to recurrence or progression

versus

QOL, functional status, age of patient and his wish

- **Patients with tumor penetrating cartilage are usually not suitable for organ saving protocol**
- **Cost effectiveness**
- **Predictive biomarkers**
- **Neoadjuvant chemotherapy – tumor response to treatment – only in clinical experiment**



Treatment choice


Non surgical treatment (Chemo – radiotherapy)

- higher S-phase fraction (of cell cycle, SPF)
- Lower share of cells with realized proliferation
- Relatively good general condition (KI, BMI, weight loss)

Surgery

- Combination of higher apoptotic threshold (higher expression of p53, bcl-2) and lower share of cells in SPF and higher share of cells G2M phase
- Advanced tumors (higher tumor volume),
- Lower expression of Ki-67
- lower micro vascular density (hypoxic tumor)

Treatment choice



The treatment strategy is usually based on international guidelines, such as NCCN. Nowhere in the whole world doesn't exist **unambiguous** consent regarding choice of the treatment modality. NCCN Guidelines distinguishes various levels of consensus.



The methods of surgical treatment of lymph node metastases

Surgery from external approach – in case of primary surgical treatment, combined with Radiotherapy/radio chemotherapy

Non surgical treatment – in case of „organ saving protocols“ - Radiotherapy/radio chemotherapy



The methods of treatment

Prescalene node biopsy (**Daniels operation**)

The **radical curative neck dissection** (Resectio venae jugularis interna en bloc sec. Crile 1906) - the upper boundary of the operation is the base of the skull and the lower boundary lies at the level of the clavicle. The sternocleidomastoid muscle, the internal jugular vein are removed.

The goal of neck dissection is complete removal of lymph nodes and vessels between the superficial and deep cervical fascia.

Functional deck dissection- the sternocleidomastoid muscle, the internal jugular vein, the accessory nerve are preserved.

An **elective neck dissection** is a neck dissection carried out in the absence of palpable lymph nodes for a primary tumor which experience has shown to have a high metastatic rate - oropharynx, hypopharynx, supraglottic larynx, the base of the tongue. The purpose of this operation is to deal with micro metastases.



Types of neck dissections (classification according to Ferlito)

ND (neck dissection)

L (left,) or R (right,) – side of neck dissection

removed region lymph nodes, described with Roman numeral to VII, in increasing order

removed non lymphatic structures

Examples:

ND (R, I-V, SCM, IJV, CN XI) – Radical neck dissection

ND (L, I-V, SCM, IJV, CN XI, CN XII) - extended Radical neck dissection with removal of n. hypoglossus

ND (I-V, SCM, IJV) – Modified radical dissection with saving n. accessorius (n. XI)


Abbreviations: ND – neck dissection , SCM – m. sternocleidomastoideus, IJV – v. jugularis interna,

CN XII – n. hypoglossus, CN XI, SAN – n. accesorius (spinal accesory nerve), ECA – a. carotis externa, ICA – a. carotis interna, CCA – a. carotis communis, CN VII – n. facialis,


CN X – n. vagus, SN – neck sympaticus, PN – n. phrenicus, SKN –skin,

PG – glandula parotis, SG – glandula submandinbularis, DCM – deep cervical muscles

Radical neck dissection ND (R, I-V, SCM, IJV, CN XI) sec. Crile



Modified radical dissection with saving n. accessorius(I-V, n.XI saved)





Prevention

Therapeutic results of Head and Neck Cancer reveal strong dependency in relation to stage – therefore prevention!

Primary – to prevent tumor formation by influence risk factors

Secondary – diagnosis of early tumor stages

Tertiary – early detection of local recurrences or distant metastasis or possibly tumor duplicity



Currently  **2** in **3**
of ALL HEAD & NECK cancers
are **DIAGNOSED** at
the **advanced** STAGE

OF these
 **H A L F** will
ALIVE after **not** be
5 YEARS

Yet if **DIAGNOSED** and
treated early  **80** -  **90** %
in the **STAGES** will **SURVIVE**

**EARLIER DIAGNOSIS AND REFERRAL CAN
IMPROVE PATIENT CHANCES OF SURVIVAL**



European campaign focused on secondary prevention

1
for
3

If you have any **ONE** of these symptoms for **THREE** weeks...

The 'One for Three' definition, developed by leading experts in head and neck cancer across Europe, states that primary healthcare practitioners should refer a patient to a head and neck specialist if they have any one of the following symptoms for more than three weeks.

Sore tongue, non-healing mouth ulcers and/or red or white patches in the mouth

Pain in the throat

Persistent hoarseness

Painful and/or difficulty swallowing

Lump in the neck

Blocked nose on one side and/or bloody discharge from the nose

WEEK 1

WEEK 2

WEEK 3

SEEK MEDICAL ADVICE

Early referral and early diagnosis saves lives. Do not delay.

For more information please visit / follow us at:

www.makesensecampaign.eu | Twitter: @MakeSenseCmpn



European support for the *Make Sense* campaign is provided by:

MERCK



Bristol-Myers Squibb



Schema of preventive evaluations, tertiary follow-up

- *Regular clinical evaluations*

 - 1st year : monthly

 - 2nd year : every 2 months

 - 3rd year : every 3-4 months

 - further years : every 6- 12 months

- *Additional evaluations:* X-ray examination of lungs/1 year , ultrasound of abdominal cavity/1 year, blood account + screening á 3 month, CT individual. After 3 years the intervals are protracting.

Tumors of nose and paranasal sinuses



Malignant melanoma of the nose

Carcinoma maxillae (T₄)





Incidence, Symptoms

- Incidence – less than 1% of all malignant tumors
- Usually 6-12 months without clinical symptoms,
- then unilateral nasal obstruction, small bleeding from the nose, frequently picture of inflammation of maxillary sinus, discharge, foetid secretion.
- In advanced tumors headache, signs of invasion of neighboring tissue – eye, cheek, regionally lymphadenopathy...



Etiology

Risk factors: hard wood dust, Nickel, isopropyl alcohol, thorotrast, yperit and other

Malignant melanoma of the nose







Investigation


- Rhino - endoscopy biopsy
- CT/MR of paranasal sinuses
- Investigation for exclusion distant metastasis : X ray of lungs, Ultrasonography of organs of stomach cavity, mamma in women and gynecology, prostate at men, PET.
- stomatology evaluation

Cancer of nose and paranasal sinuses - TNM classification



- T1.** Tumour limited to the mucosa with no erosion or destruction of bone
- T2.** Tumour causing bone erosion or destruction, including extension into hard palate and/or ...
- T3.** Tumour invades any of the following: bone of posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, ethmoid sinuses
- T4.** Tumour invades any of the following: anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve V2, nasopharynx. clivus

Cancer of hard palate





Therapy

Surgical treatment is preferred.

St. I, II – surgery (no risk factors present)

St. III, IV – surgery + radiotherapy (+- adjuvant chemotherapy).

+ surgery for locoregional lymphnodes – only in their CT or MR positivity



Surgical approaches



- **Transfacial** *Lateral rhinotomy with various modifications* enabling approach to both partial and total maxillectomies. (*Weber-Ferguson*)
- **Endoscopic** — benign tumors, inverted papilloma, carcinomas — CAS (computer assisted surgery)
- **Sublabial rhinotomy** („*midfacial degloving*“) small tumors of anterior wall of maxillae
- **Combined craniofacial** — intracranial spread of tumor + neurosurgery bicoronal section



Surgical therapy – external approach

- **Maxillary sinus** – parcial or total maxilectomy.
- **Ethmoid sinus** - external ethmoidectomy sec. „Moure“
- **Frontal sinus** classical rhinosurgery - Jansen- Ritter, Riedel, Killian.
- **Sphenoid sinus** - sphenoidectomy via sublabialis, transseptalis.


Lateral rhinotomy Weber- Ferguson






Maxillectomy according to Memorial Sloan Kettering Cancer Center (Spiro 1997)


- „limited“ maxillectomy – every maxilectomy with removal only one wall of antrum Highmori
- „subtotal“ maxillectomy – removal of at least two walls of antrum Highmori
- „total“ maxillectomy – all maxilla is removed



A

Midfacial degloving





^cSee Principles of Surgery (SURG-A).

^dSee Principles of Radiation Therapy (MAXI-A).

^eSee Principles of Systemic Therapy (CHEM-A).


^gFor adenoid cystic tumors and minor salivary gland tumors, see (SALI-A).

^hAdverse features include positive margins or extracapsular nodal spread (See Discussion).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Cancer of maxillary sinus



- Very late diagnosis
- Treatment worsening quality of life



Surgery of cancer of paranasal sinuses

Multidisciplinary approach


(otorhinolaryngology, plastic surgeon, neurosurgeon,
stomatosurgeon)

- Phase of resection
- Phase of reconstruction



Phase of resection

- Resection of primary tumor
 - T1, T2 – limited or partial maxillectomy
 - T3, T4 - total maxillectomy, extended total maxillectomy, exenteration of orbitae
- Revision of parapharyngeal space (N_0), neck dissection ($N>0$)



Phase of reconstruction

- Microsurgical flaps
(in one surgery)
- prosthetic solution
 - obturators and epithesis
 - tooth prosthesis
 - eye prosthesis




Prosthesis after surgery – covering defect





Closing the defect - vessel microsurgery





- m. latissimus dorsi, m. serratus ant. - Muscle – skin flap
- China flap - Skin + subcutaneous flap
- Bone-muscle- flap




Ca spinocellulare maxillae l.dx. cT4








Month after surgery





Skin used for reconstruction of the orbit



Skin used for palate reconstruction

Měsíc po operaci




Kůže použitá pro
rekonstrukci patra


Kůže použitá pro
rekonstrukci
orbity

Reconstruction in one step

- + Enabling sufficient radicality
- + Shorter healing after surgery
- + better cosmetic effect
- difficult possibility of detecting recurrences in operating cavity



Survival of patients with malignant tumors of nose and paranasal sinuses





60. year old patient JV

- Nasal polyposis for years
- 9/2009 oedema of right eye, blocked nose, without diplopia
- Tumor adhering to dura mater
- Histology: **not differentiated carcinoma karcinom. pT4b
NOMO**



CT/2/14
Axial F->H
NATIV

A

CT/2/10
Axial F->H
NATIV

A

1949/2/18
60Y M
4284-6817/09
2009/9/14
11:32:09



DFOV: 18.80 x 18.80cm

CT/550/9
Coronal A->P
cor
SCANLUX 300

H

1949/2/18
60Y M
6817/09
2009/9/14
11:32:09



R

120.0 kV
599.0 mA
Pixel size: 0.313 mm
Position: 85.4 mm
W: 300 L: 35

F

CT/5/50
Axial F->H
SOFT
SCANLUX 300

A

1949/2/18
60Y M
4284-6817/09
2009/9/14
11:32:09




R

120.0 kV
599.0 mA
Pixel size: 0.367 mm
Position: 48.6 mm
W: 400 L: 40

P


DFOV: 18.80 x 18.80cm

14.10.2009 Exenteratio orbitae l.dx, resectio maxillae partialis l.dx, resectio baseos fossae cranii anterior, ethmoidectomia l. utr., transplantatio durae matris fossae cranii ant. l.dx., reconstructio defectus plastica cum musculus latissimus dorsi





Neurosurgery – resection of dura mater, replaced by synthetic dura





Defect closed with musculocutaneous flap
from m. latissimus dorsi microsurgical
anastomosis on v.a a. facialis




Overall survival – 8
year, good QOL



-
- 2009 – Adjuvant CHRT
 - Follow up by NMR/ CT
 - 11/2012 swelling of head on contralateral side - sinusitis frontalis a etmoidalis with periorbital swelling
 - Histology middle turbinate: Chronic inflammatory changes, without tumor
 - Exitus letalis - 11.4.2017 low diff. ductal adenocarcinoma of head of **pancreas**



Carcinoma maxillae (T₄)






Ca spino maxillae

pT4 N0 M0



Cancer of pharynx




Nasopharynx
C11

Oropharynx
C10

Hypopharynx
C13

Ösophagus
C15





Cancer of epipharynx (C 11) - TNM classification

T1. Tumour confined to nasopharynx

T2. Tumour extends to soft tissues

T2a. Tumour extends to oropharynx and/or
nasal cavity without parapharyngeal
extension*



T2b. Tumour with parapharyngeal extension*



Cancer of epipharynx (C 11) - TNM classification

T3 Tumour invades bony structures and/or paranasal sinuses

T4 Tumour with intracranial extension and/or involvement of cranial nerves, infratemporal fossa, hypopharynx, orbit, or masticator space





N – Regional lymph node (nasopharynx)

NX Regional lymph nodes cannot be assessed

N0 regional lymph node metastasis

N1 Unilateral metastasis, in lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa

N2 Bilateral metastasis in lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa


N3 Metastasis in lymph node(s) greater than 6 cm in dimension or in the supraclavicular fossa

N3a. greater than 6 cm in dimension

N3b. in the supraclavicular fossa

Note: Midline nodes are considered ipsilateral nodes.

Cancer of epipharynx invading roof, extending into torus tubaris – T₂



CT/4/13
Axial F->H
NATIV

A

FN U sv. Anny v Brne
HUSAR ZDENEK
540916/4123
1954/9/16
53Y M
4284-6418/07
2007/10/16
14:57:08



120.0 kV
140.0 mA
Pixel size: 0.512 mm
Position: -27.0 mm
W: 350 L: 40
P
DFOV: 26.20


Ca epipharyngis T4N2c

53 year, random finding, hypacusis
mixta. dx.

CT/4/21
Axial F->H
NATIV

A

FN U sv. Anny v Brne
HUSAR ZDENEK
540916/4123
1954/9/16
53Y M
4284-6418/07
2007/10/16
14:57:08



120.0 kV
122.0 mA
Pixel size: 0.512 mm
Position: -67.0 mm
W: 350 L: 40
P
DFOV: 26.20 x 26.20cm



CT/3/20
Axial F->H
K.L.

FN U sv. Anny v Brně
HUSAR ZDENEK
540916/4123
1954/9/16
53Y M
4284-6418/07
2007/10/16
14:57:08

CT/3/21
Axial F->H
K.L.

FN U sv. A
HUSA
54
42

140.0 kV
455.0 mA
Pixel size: 0.438 mm
Position: -5.3 mm
W: 132 L: 35

DFOV: 22.40 x 22.40cm

140.0 kV
455.0 mA
Pixel size: 0.438 mm
Position: -2.8 mm
W: 132 L: 35

DFOV: 22.40 x 22.40cm


Ca epipharyngis
T4N2c
the same patient



Tumors of epipharynx - histologic findings

- Carcinomas (WHO classification) –
 - Type 1 – carcinoma spinocellulare with keratinisation
 - Type 2 – carcinoma spinocellulare without keratinization
 - Type 3 – low differentiated or undifferentiated carcinomas
- Tumors of soft tissue: Juvenile angiofibroma, paraganglioma (chemodectoma).
- Malignant lymphoma
- Miscellanea: melanoblastomas, chordomas, craniopharygneomas, neuroblastomas

Lymphoepithelioma of epipharynx (Schmincke- Regaud)





Nasoharyngeal tumors etiology

Food habits: salt fish (nitrosamins), croton oil –
promoters of some lymphoblastic clons **virus**
Epstein Barr (EB virus)



Symptoms

- **Ear** – sensation of fullness in ear, worsening of hearing, tinnitus, pain in the ear
- **Nose** - obstruction, bleeding
- **Pharyngeal** - sensation of foreign body
- **Eye** - diplopy, ophthalmoplegia
- **Neurologic** - trigeminal hypesthesia,
- Trotter trias: trigeminal neuralgia, hypacusis conductiva, asymetry of soft palate from paresis on involved side.

Clinical finding: bumpy, exulcerated, rough, mostly exophytic tissue in epipharynx

CT/3/17
Axial F->H
K.L.
IOMERON 300



Ca epipharyngis
T4





Therapy

- Cancer, current protocol: Curretage of epipharynx + concomitant chemoradiotherapy. 55 - 70 Gy. Eventually neck dissection (in case of persistence arter CHRT)
- Lymphomas radiotherapy 40-45 Gy.




Oral cavity anatomic sublocalisations


- Lips
- Mucosa membrane of lips and cheek
- Retro molar region
- Bucoalveolar sulcus
- Superior alveolus and gingiva
- Inferior alveolus and gingiva
- Hard palate
- Tongue before papillae circumvallate
- Base of oral cavity




TNM classification

- TNM – borders 2cm -4 cm, infiltration of corticalis and deep muscles of tongue
- Important – thickness of tumor– even in clinically negat. neck in tumor more than 5mm thick neck dissection necessary
- Infiltration of bone - T4
- Reconstruction with help of tongue or cheek flaps or soft palate or microsurgery flaps






Laser surgery of tongue





Laser surgery of tongue





Cancer of oropharynx





what we knew

Cancer of pharynx and larynx were considered to have the same cause - smoking...



Many of epidemiologic studies of molecular pathology document, that human papillomavirus (HPV), especially type 16 is etiologically connected with oropharyngeal cancer

- Gillison 2009



HPV and prognosis of OSCC

Prognosis of HPV related cancer is better than tobacco related cancer. Expression of p16 in HNSCC marked group of HPV induced tumors with good prognosis

Treatment of HPV positive OSCC

- ✓ Organ saving strategy should be more successful.
- ✓ Better response on induction chemo and chemoRT

Fakhry J Nat Inst 2008: 100, 261

Comparison of HPV+ a HPV- tumors

	HPV+	HPV -
Incidence	↑	↓
Age	<50	50-70
Risk factors	oral sex	smoking, alcohol
Histology	low differentiated, nonkeratinizing, bazaloid	middle to good differentiated, keratinizing
Markers	p16	p53
TNM klassifikation	Lower T N++	higher T N+
Metastasis in lymphnodes	cystic	more homogenous
Chemoradiosenzitivity	high	lower
Prognosis	good	worse
OS (5 let)	>80%	< 40-50%

Tumors of oropharynx symptoms

At least half year without clinical symptoms:

- Painful dysphagia
- Pain in the ear
- Feeling of foreign body in the pharynx
- bleeding
- trismus

Clinical finding: hard knot covered with mucous membrane (induration of the tonsil), later ulceration, oral fetor. Important – unilateral changes, palpation !



Ca spino palati mollis cT2-3 cN2b M0 st. IVa

histology: low
differentiated
nonkeratinising
squamocelular
cancer

p16 negative

MKN: C051

MKN-O:

M-8070/3 3






Retromolar trigonum cancer T2

Ca spino palati molle T1



Left tonsil cancer






Cancer of the base of the tongue



Tumors of oropharynx TNM classification


- T1. Tumour 2 cm or less in greatest dimension
- T2. Tumour more than 2 cm but not more than 4 cm in greatest dimension



T3. Tumor more than 4 cm in greatest dimension

T4a. Tumor invades any of the following: larynx deep/ extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), medial pterygoid, hard palate, and mandible

T4b. Tumor invades any of the following: lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, skull base; or encases the carotid artery





Therapy of oropharyngeal cancer

Radically resected tumors

Radical surgery (safe margins, R_0) + neck dissection+
actinotherapy vs. **Primary nonsurgical treatment**

Actinotherapy LD 55-60 Gy + boost 10-15 Gy +
chemotherapy in risk factors, always prophylactic lymph
node actinotherapy.

Lymphomas 40-45 Gy.

Advanced not radically resected tumors

Palliative radiotherapy or chemo-radiotherapy with
attempt of curative treatment or only BSC

Routes of access for tumors of the mouth and pharynx

Transoral(1)


- Limited indications – small accessible tumors

External approaches saving mandible (3-5)

- Lateral pharyngotomy
- Suprahyoid median pharyngotomy


External approaches with mandibulotomy (-ectomy) (2)

- Lateral pharyngotomy with removal of mandibular angle
- Trans mandibular buco-pharyngectomy (BPTM)
- BPTM with resection of lateral mandible segment




Ca spino gingivae of mandibulae left –
pT2N2bM0. Partial mandibulectomy
without discontinuance









Buccopharyngectomy